NCT00529763 2023-05-08
Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects
Bristol-Myers Squibb
Phase 2 Completed
Clinical Trials
9 trialsNCT01460160 2021-12-08
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
Bristol-Myers Squibb
Phase 2 Completed
NCT02546791 2017-07-26
PASS
Bristol-Myers Squibb
Completed
NCT01357655 2017-03-14
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
Bristol-Myers Squibb
Phase 2 Terminated
NCT01188278 2016-09-30
Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey
Bristol-Myers Squibb
Completed
NCT01218477 2016-06-17
Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00982488 2016-01-22
START rollover
Bristol-Myers Squibb
Phase 2 Completed
NCT00978731 2011-04-28
Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study
Bristol-Myers Squibb
Phase 1 Completed
NCT00362466 2009-11-20
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
Bristol-Myers Squibb
Phase 3 Terminated